公开(公告)号：US20160222464A1

公开(公告)日：2016-08-04

申请号：US15014074

申请日：2016-02-03

Applicant: Mor Research Applications Ltd.

Inventor： Smadar Avigad ,  Isaac Yaniv

IPC: C12Q1/68

Abstract: The present invention relates to prognostic methods and kits for the assessment and monitoring of relapse-free or disease-free survival of ALL patients. The detection is based on the use of detecting nucleic acids, specific for determination of the expression of at least one of miR-151-5p and miR-451 in a test sample. The invention thereby also provides methods and kits for monitoring and early diagnosis of cancerous disorders associated with low miR-151-5p and/or miR-451 expression, specifically ALL, and appropriate associated treatments thereof.

Abstract translation: 本发明涉及用于评估和监测ALL患者无复发或无病生存的预后方法和试剂盒。 该检测基于检测核酸的用途，其特异性用于确定测试样品中miR-151-5p和miR-451中的至少一种的表达。 因此，本发明还提供了用于监测和早期诊断与低miR-151-5p和/或miR-451表达（特别是ALL）相关的癌症的方法和试剂盒及其适当的相关治疗。

公开(公告)号：US10557173B2

公开(公告)日：2020-02-11

申请号：US15014074

申请日：2016-02-03

Applicant: Mor Research Applications Ltd.

Inventor： Smadar Avigad ,  Isaac Yaniv

IPC: C12Q1/68 ,  C12Q1/6886

Abstract: The present invention relates to prognostic methods and kits for the assessment and monitoring of relapse-free or disease-free survival of ALL patients. The detection is based on the use of detecting nucleic acids, specific for determination of the expression of at least one of miR-151-5p and miR-451 in a test sample. The invention thereby also provides methods and kits for monitoring and early diagnosis of cancerous disorders associated with low miR-151-5p and/or miR-451 expression, specifically ALL, and appropriate associated treatments thereof.

公开(公告)号：US11045489B2

公开(公告)日：2021-06-29

申请号：US16567233

申请日：2019-09-11

Applicant: MOR RESEARCH APPLICATIONS LTD.

Inventor： Smadar Avigad ,  Isaac Yaniv ,  Keren Shichrur

IPC: C12Q1/68 ,  A61K31/7105 ,  G01N33/574 ,  C12N15/113 ,  C12Q1/6886 ,  A61K31/4025 ,  A61K39/395

Abstract: Described herein are methods for determining the prognosis of a patient diagnosed with Acute Lymphoblastic Leukemia (ALL), and particularly determining the risk of disease relapse following standard treatment. Also described are systems of treatment that are directed by a health care provider, and which include the described prognostic methods and the treatments recommended for patients determined to have a specific relapse risk.